OB/GYN Clinical Alert – September 1, 2010
September 1, 2010
View Issues
-
New Insights into VBACs and Maternal and Neonatal Outcomes
Although some aspects of vaginal birth after cesarean delivery (VBAC) have been covered in previous OB/GYN Clinical Alert issues, I cannot pass up an opportunity to comment on two papers appearing in the June issue of Obstetrics & Gynecology. -
Stress Incontinence After Midurethral Sling: Now What?
I love this article. It's relevant to our daily practice, but, more importantly, it verbalizes the same issues that both physicians and patients want clarified. -
Paclitaxel and Carboplatin: A Relevant Combination in Uterine Carcinosarcoma
Carcinosarcoma of the uterus is a rare condition accounting for less that 4% of all uterine neoplasms. Previous work has identified that the most active single agents are platinum, ifosfamide, paclitaxel, and doxorubicin. -
Special Feature: Tranexamic Acid: Nonhormonal Treatment for Heavy Menstrual Bleeding
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States. -
Pharmacology Watch: Weight-loss Drug Effective Without Cardiac Side Effects?
In this issue: Lorcaserin submitted for FDA review, FDA advisory panel votes against phentermine/topiramate, mixed vote on rosiglitazone, advisory panel votes to remove breast cancer indication from bevacizumab labeling, no increase in seizures found with DTaP vaccine, new REMS for quinine. -
Clinical Briefs in Primary Care supplement